Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 10:40PM GMT
Release Date Price: $91.38 (+2.13%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Good afternoon. Welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior SMID Biotech analyst here at the firm. It's my pleasure to have our next company presenting, Apellis Pharmaceuticals. Sitting to my left is CEO, Cedric Francois; as well as CFO, Tim Sullivan. Good afternoon, guys. Thanks for making the trip over to Las Vegas to see us.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you. Great to be here.

Timothy E. Sullivan
Apellis Pharmaceuticals, Inc. - CFO & Treasurer

Thank you.

Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

So I don't think most people need any intro on the company, but for those who do, maybe Cedric for 2 minutes, can you just tell us all about the company, and then we can go to specifics on Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot